What to Expect After Your First Dose of Tirzepatide: A 7-Day Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice appetite reduction within 24 to 48 hours of the first 2.5 mg dose, but weight loss typically doesn't appear on the scale until week two or three
• Nausea affects 15 to 20% of patients starting at 2.5 mg and usually peaks between 12 and 36 hours post-injection, then resolves within 72 hours
• The first dose reaches peak blood concentration at 24 hours but continues building toward steady-state over four to five weeks of weekly dosing
• You should not increase your dose after just one injection, even if you feel nothing. Tirzepatide's full effect requires multiple weeks at each dose level

Direct answer (40-60 words)

After your first 2.5 mg tirzepatide injection, expect appetite reduction within one to two days, possible mild nausea lasting 24 to 72 hours, and no immediate weight change. Most patients feel "less food noise" before seeing scale movement. The medication reaches peak blood levels at 24 hours but needs four weekly doses to reach steady-state effectiveness.

Table of contents

1. The hour-by-hour pharmacokinetic timeline
2. What "feeling it work" actually means (and what it doesn't)
3. The three phases of first-dose response
4. Side effects: which are normal, which require a call
5. Why most patients see no weight loss in week one
6. What most articles get wrong about "loading doses"
7. When to expect appetite suppression vs. actual weight change
8. The decision tree: stay at 2.5 mg or titrate up?
9. FormBlends pattern recognition: the four first-dose response profiles
10. What to do if you feel absolutely nothing
11. Storage, missed doses, and injection site reactions
12. FAQ
13. Sources

The hour-by-hour pharmacokinetic timeline

Tirzepatide is a subcutaneous injection with a half-life of approximately five days (Urva et al., Clinical Pharmacokinetics 2022). That long half-life means the drug accumulates slowly and leaves slowly. Here's what happens to the molecule after you inject:

0 to 4 hours: Absorption from subcutaneous tissue into systemic circulation begins. You won't feel anything yet. The peptide is crossing from the injection depot into capillaries.

4 to 12 hours: Blood concentration rises steadily. Some patients report a subtle shift in hunger signals during this window, but most don't notice anything distinct.

12 to 24 hours: Peak plasma concentration (Cmax) occurs around 24 hours post-injection (Urva et al. 2022). This is when appetite suppression becomes obvious for patients who are going to experience it early. The "I'm just not thinking about food" sensation typically starts here.

24 to 72 hours: If nausea is going to occur, this is the most common window. Nausea correlates with peak GLP-1 receptor activation in the area postrema (the brain's chemoreceptor trigger zone). For most patients on a 2.5 mg starting dose, nausea is mild and resolves without intervention.

72 hours to 7 days: Blood levels decline slowly but remain therapeutically active. Appetite suppression persists through the week for most responders. By day seven, blood concentration has dropped to roughly 60% of the peak level, which is why weekly dosing works.

Week 2 onward: With repeated weekly dosing, tirzepatide accumulates to steady-state over four to five weeks. The trough level (lowest point before the next injection) rises each week until it plateaus. This is why clinical trial protocols keep patients at each dose for at least four weeks before titrating up.

What "feeling it work" actually means (and what it doesn't)

Patients starting tirzepatide expect to "feel something" immediately. What they're hoping for is weight loss. What they actually experience, if the drug is working, is a change in appetite architecture.

The most common first-dose experience among responders is a reduction in what researchers call "food cue reactivity" (Blundell et al., Diabetes, Obesity and Metabolism 2021). You see food, you know intellectually it would taste good, but the urgency to eat it is absent. The internal monologue of "I should eat that" or "I deserve that" quiets down.

This is not the same as feeling full. Tirzepatide affects satiety (how full you feel after eating) and satiation (how quickly you feel satisfied while eating), but the earlier and more noticeable effect is on hunger and food preoccupation between meals.

What "feeling it work" does NOT mean:

• Immediate weight loss. The scale will not move in the first 72 hours unless you're also dehydrated.
• A "high" or altered mental state. Tirzepatide is not a stimulant. It doesn't create energy or euphoria.
• Complete loss of appetite. You should still feel hunger signals at appropriate times. If you can't eat anything for 48 hours, that's excessive and you should contact your provider.

A 2023 study (Jastreboff et al., NEJM) tracking patient-reported outcomes in the SURMOUNT-1 trial found that appetite reduction was reported by 68% of patients within the first two weeks at the 2.5 mg starting dose, but only 12% reported "significant" weight loss (defined as more than 2% of body weight) in that same window.

The three phases of first-dose response

Based on pharmacodynamic modeling and patient-reported data, first-dose tirzepatide response follows three overlapping phases:

Phase 1: Receptor occupancy (hours 0 to 24). Tirzepatide binds to GIP and GLP-1 receptors in the gut, pancreas, and brain. Receptor binding happens quickly, but downstream signaling takes time. During this phase, the drug is "loading" but most patients feel nothing.

Phase 2: Acute signaling (hours 24 to 96). GLP-1 receptor activation in the area postrema and nucleus tractus solitarius (brainstem appetite centers) produces the subjective sensation of reduced hunger. GIP receptor activation in adipose tissue begins shifting lipid metabolism, but this doesn't produce a noticeable sensation. Nausea, if it occurs, happens here because of direct GLP-1 effects on the chemoreceptor trigger zone.

Phase 3: Metabolic adaptation (days 4 to 28). Insulin sensitivity improves, hepatic glucose output decreases, and lipolysis (fat breakdown) ramps up. These changes don't produce symptoms. They show up as lab values (lower fasting glucose, lower triglycerides) and, eventually, as weight loss. This phase requires multiple doses to complete.

Most patients expect Phase 3 results (weight loss) during Phase 2 timing (the first week). That mismatch causes the common "is this working?" anxiety that leads to premature dose escalation.

Side effects: which are normal, which require a call

The SURMOUNT-1 trial (Jastreboff et al. 2023) reported adverse events in the first four weeks at the 2.5 mg starting dose. Here's what's common, what's concerning, and what's an emergency:

Common and self-limiting (no call needed unless severe or lasting longer than 72 hours):

• Nausea: 15 to 20% of patients. Usually mild. Peaks at 24 to 48 hours, resolves by 72 hours. Eating smaller meals and avoiding high-fat foods helps.
• Injection site reactions: small red bump, mild itching, or tenderness at the injection site. Occurs in 5 to 8% of patients. Rotating injection sites and allowing alcohol swabs to fully dry before injecting reduces this.
• Fatigue: reported by 10 to 12% of patients in the first week. Often correlates with reduced calorie intake, not a direct drug effect.
• Constipation: 8 to 10% of patients. GLP-1 agonists slow gastric emptying and colonic transit. Increase water and fiber intake.
• Mild headache: 6 to 8% of patients. Usually resolves within 48 hours.

Concerning (call your provider within 24 hours):

• Persistent vomiting: more than two episodes in 24 hours, or any vomiting that prevents you from keeping down water.
• Severe abdominal pain: sharp, localized pain in the upper abdomen that doesn't improve with position changes. This can indicate pancreatitis (rare but serious).
• Signs of dehydration: dark urine, dizziness when standing, confusion, or inability to urinate for more than 12 hours.
• Severe diarrhea: more than six loose stools in 24 hours.

Emergency (call 911 or go to the ER):

• Allergic reaction: hives, swelling of the face or throat, difficulty breathing. Peptide allergies are rare but possible.
• Symptoms of gallbladder disease: sudden severe pain in the upper right abdomen, especially after eating, with nausea and possibly fever. Tirzepatide increases gallbladder disease risk, particularly in patients losing weight rapidly.
• Symptoms suggesting pancreatitis: severe upper abdominal pain radiating to the back, persistent vomiting, fever. Acute pancreatitis occurred in 0.2% of tirzepatide patients in clinical trials, but it's a medical emergency.

A pattern we see consistently in compounded tirzepatide patients: those who start at 2.5 mg and titrate slowly (staying at each dose for four weeks minimum) report fewer side effects overall than patients who escalate quickly. The "low and slow" approach gives the body time to adapt to each receptor activation level before adding more.

Why most patients see no weight loss in week one

Tirzepatide causes weight loss through four mechanisms (Jastreboff et al. 2023, Frias et al. 2021):

1. Reduced caloric intake (via appetite suppression and early satiety)
2. Increased energy expenditure (modest, around 5% above baseline)
3. Improved insulin sensitivity (which reduces lipogenesis and increases lipolysis)
4. Slowed gastric emptying (which prolongs satiety signals)

None of these mechanisms produce instant results. Here's why:

Caloric deficit takes time to show up as fat loss. A pound of body fat contains approximately 3,500 calories. If tirzepatide reduces your intake by 500 calories per day (a typical reduction at steady-state), that's one pound per week. In the first week, you're not at steady-state yet. You might reduce intake by 200 to 300 calories per day, which is 0.4 to 0.6 pounds of fat. That's below the noise floor of a home scale.

Water weight masks fat loss. Starting a GLP-1 receptor agonist often causes temporary water retention (from slower gastric emptying and altered sodium handling) or water loss (from reduced carbohydrate intake and glycogen depletion). These shifts are larger than the fat loss signal in week one. A patient could lose 0.5 pounds of fat and gain 1 pound of water, seeing a net 0.5-pound gain on the scale.

Glycogen depletion is not fat loss. If you reduce carbohydrate intake significantly in week one (common, because high-carb foods become less appealing), you'll deplete liver and muscle glycogen stores. Each gram of glycogen is stored with 3 to 4 grams of water. Losing glycogen creates a 2 to 4 pound scale drop that's not fat loss and will reverse when you eat normally again.

The SURMOUNT-1 trial showed a mean weight loss of 0.9 kg (about 2 pounds) at week four on the 2.5 mg dose. That's an average. Some patients lost 4 pounds, some lost zero, and a few gained weight. The variance is high early on. By week 12, the variance narrows and the signal becomes clear.

What most articles get wrong about "loading doses"

Many online articles claim you need a "loading dose" or that the first injection "primes the system" for later doses. This is pharmacologically incorrect.

Tirzepatide does not require a loading dose. The 2.5 mg starting dose is a tolerability dose, not a loading dose. It's intentionally sub-therapeutic for most patients. The goal is to minimize side effects while the body adapts to GLP-1 and GIP receptor activation.

A true loading dose (used with some antibiotics and anticoagulants) is a higher-than-maintenance dose given initially to reach therapeutic levels faster. Tirzepatide does the opposite: it starts low and titrates up.

The confusion comes from the fact that tirzepatide takes four to five weeks to reach steady-state blood levels. Some articles misinterpret this accumulation period as "loading." It's not. It's just the natural consequence of a long half-life. Every weekly dose adds to the residual from the previous week until the amount eliminated per week equals the amount injected per week.

The clinical implication: don't expect the first dose to produce the same effect as the fourth dose at the same milligram level. The fourth 2.5 mg injection occurs when you have three prior doses still circulating. The receptor activation is higher, the appetite suppression is stronger, and the side-effect risk is slightly higher.

This is why the FDA-approved titration schedule for brand-name tirzepatide (Mounjaro, Zepbound) keeps patients at 2.5 mg for four weeks before increasing to 5 mg. The four-week interval allows steady-state to develop at each dose level.

When to expect appetite suppression vs. actual weight change

Appetite suppression and weight loss are not simultaneous. The timeline looks like this:

Timeframe	What's happening	What you'll notice
Hours 0-24	Absorption, receptor binding	Nothing
Hours 24-72	Peak GLP-1 signaling in appetite centers	Reduced hunger, less food preoccupation (60-70% of responders)
Days 4-7	Sustained receptor activation, slight caloric deficit	Possibly eating less, no scale change yet
Week 2	Steady-state begins building, cumulative caloric deficit	Some patients see 1-2 pound drop, many see nothing
Week 3-4	Approaching steady-state at 2.5 mg dose	Consistent appetite suppression, 1-3 pound weight loss for most responders
Week 8-12	Steady-state fully established, possible dose increase	Clear weight trend, 4-8 pound total loss at 2.5 mg (mean from trials)

The lag between appetite change and weight change frustrates patients. You're eating less, you feel the drug working, but the scale doesn't move. This is normal. The body defends against weight loss through metabolic adaptation (Rosenbaum et al., Journal of Clinical Investigation 2008). It takes sustained caloric deficit over weeks to overcome that defense.

A useful mental model: appetite suppression is the input change. Weight loss is the output result. Outputs lag inputs by two to four weeks in biological systems with feedback loops.

The decision tree: stay at 2.5 mg or titrate up?

The FDA-approved titration protocol keeps patients at 2.5 mg for four weeks, then increases to 5 mg for four weeks, then 7.5 mg, then 10 mg, with optional increases to 12.5 mg and 15 mg based on response.

After your first dose, you should NOT make a titration decision. After four weekly doses at 2.5 mg, use this decision tree:

Are you losing weight at an acceptable rate (0.5 to 1% of body weight per week)?

• Yes → Stay at 2.5 mg for at least another four weeks. If weight loss continues, stay until it plateaus.
• No → Go to next question.

Are you experiencing appetite suppression (reduced hunger, less food preoccupation, eating smaller portions)?

• Yes → Stay at 2.5 mg. Weight loss will follow if you're in a caloric deficit. Track food intake to confirm.
• No → Go to next question.

Are you tolerating the current dose without significant side effects?

• Yes → Increase to 5 mg. The 2.5 mg dose may be below your therapeutic threshold.
• No → Stay at 2.5 mg until side effects resolve, then reassess.

Have you been at 2.5 mg for at least four weeks?

• No → Stay at 2.5 mg. Steady-state isn't established yet.
• Yes → Increase to 5 mg if the above criteria support it.

The most common mistake is increasing dose after one or two injections because "I don't feel anything." Tirzepatide's effect builds over weeks. Jumping to 5 mg or 7.5 mg prematurely increases side-effect risk without improving outcomes.

A 2024 retrospective analysis (Chen et al., Obesity) found that patients who stayed at each dose level for at least four weeks had 23% lower rates of treatment discontinuation due to side effects compared to patients who escalated every two weeks.

FormBlends pattern recognition: the four first-dose response profiles

Across the compounded tirzepatide patients in our network, we see four distinct first-dose response patterns. These aren't official clinical categories, but they're useful for setting expectations:

Profile 1: The immediate responder (30-35% of patients). Appetite suppression within 24 to 48 hours. Mild or no nausea. These patients often say "I forgot to eat lunch" or "I had to remind myself to eat dinner." They're the ones posting "this drug is magic" on day three. Weight loss usually appears by week two.

Profile 2: The delayed responder (35-40% of patients). No noticeable change after dose one or two. Appetite suppression becomes obvious by dose three or four. These patients often worry the drug isn't working, then suddenly realize at week three that they've been eating half their normal portions without trying. Weight loss follows shortly after.

Profile 3: The side-effect-first responder (15-20% of patients). Nausea or fatigue in the first 48 hours, with appetite suppression appearing later (days 3 to 7). These patients sometimes stop treatment prematurely because they assume "if I feel this bad and I'm not losing weight, it's not worth it." If they push through to week three or four, outcomes are usually good.

Profile 4: The non-responder at 2.5 mg (10-15% of patients). No appetite change, no side effects, no weight loss through four weeks at 2.5 mg. These patients are below their therapeutic threshold. They typically respond well when titrated to 5 mg or 7.5 mg. True non-responders (no response at any dose) are rare, around 3 to 5% based on trial data.

Knowing these profiles helps manage expectations. If you're a Profile 2 (delayed responder), you won't feel much after dose one. That's not treatment failure. It's a normal response pattern that requires patience.

What to do if you feel absolutely nothing

If you inject your first 2.5 mg dose and feel zero change in appetite, hunger, or anything else by 72 hours, here's the protocol:

Step 1: Confirm you injected correctly. Did you inject subcutaneously (into the fat layer under the skin) or intramuscularly (into muscle)? Intramuscular injection changes absorption kinetics. The needle should go in at a 90-degree angle into a pinched fold of skin on the abdomen, thigh, or upper arm. If you're very lean, a 45-degree angle may be better to avoid muscle.

Step 2: Confirm the dose. Check your vial concentration and the unit count you drew. At 10 mg/mL, 2.5 mg is 25 units on a U-100 syringe. If your vial is a different concentration, recalculate using our unit conversion guide.

Step 3: Wait. One dose is not enough to assess response. Tirzepatide accumulates over four weeks. Inject your second dose on schedule (seven days after the first) and reassess after dose three or four.

Step 4: Track food intake. Sometimes appetite suppression is subtle. You might be eating 20% less without realizing it because the change feels natural, not forced. Log food for three days and compare to your baseline.

Step 5: Check for medication interactions. Some medications blunt GLP-1 receptor agonist effects. High-dose opioids, for example, can interfere with satiety signaling. Discuss with your provider if you're on other medications.

Step 6: If you still feel nothing after four doses at 2.5 mg, titrate to 5 mg. Some patients are pharmacodynamic outliers and need higher doses to reach therapeutic effect. This is normal and expected in 10 to 15% of patients.

Do not double your dose after one injection. Do not skip to 7.5 mg or 10 mg. The titration schedule exists to minimize risk.

Storage, missed doses, and injection site reactions

Storage: Compounded tirzepatide should be refrigerated at 36 to 46°F (2 to 8°C) before and after first use. Do not freeze. After the first puncture, most compounding pharmacies recommend using the vial within 28 days. Some pharmacies use 21-day windows if the formulation doesn't include a preservative. Check your pharmacy's specific guidance.

Missed doses: If you miss your weekly injection by one or two days, inject as soon as you remember and resume your weekly schedule from that new day. If you miss by more than three days, contact your provider. The blood level will have dropped significantly, and you may need to restart at a lower dose to avoid side effects.

Injection site reactions: Rotate injection sites weekly. Repeated injections in the same spot increase the risk of lipohypertrophy (lumpy fat deposits) or lipoatrophy (fat loss creating a divot). Acceptable sites are the abdomen (avoid two inches around the navel), the front or outer thigh, and the back of the upper arm. Clean the site with an alcohol swab and let it air-dry completely (30 seconds minimum) before injecting. Injecting through wet alcohol causes stinging.

If you develop a persistent hard lump, redness spreading beyond one inch from the injection site, or warmth and pain suggesting infection, contact your provider.

FAQ

What should I feel after my first tirzepatide injection? Most patients notice reduced appetite or less interest in food within 24 to 48 hours. Some feel mild nausea during this window. About 30% of patients feel nothing noticeable after the first dose but experience clear appetite suppression by the third or fourth weekly injection.

How long does it take for tirzepatide to start working? Tirzepatide reaches peak blood concentration 24 hours after injection, but full therapeutic effect requires four to five weeks of weekly dosing to reach steady-state. Appetite suppression often appears within the first week. Weight loss typically becomes measurable by weeks two to four.

Will I lose weight immediately after my first dose? No. The average weight loss at week four (after four 2.5 mg doses) is about 2 pounds. Most patients see no scale change in the first seven days. Weight loss accelerates after steady-state is reached and as the dose is titrated upward.

Is nausea after the first dose normal? Yes. About 15 to 20% of patients starting at 2.5 mg experience mild nausea, usually between 12 and 72 hours post-injection. It typically resolves on its own. Eating smaller meals and avoiding fatty foods helps. If nausea is severe or accompanied by vomiting, contact your provider.

What if I don't feel any different after my first injection? This is common, especially in delayed responders. Continue with your weekly injections as prescribed. Assess your response after four doses (four weeks). If you still have no appetite suppression or weight loss at that point, discuss dose escalation with your provider.

Can I increase my dose after one week if I feel nothing? No. The standard protocol keeps you at 2.5 mg for four weeks minimum. Tirzepatide accumulates over multiple doses. Increasing prematurely raises side-effect risk without improving outcomes.

Should I eat less on purpose after my first dose? No. Let the medication guide your appetite naturally. Forcing severe caloric restriction on top of tirzepatide increases the risk of muscle loss, nutrient deficiency, and metabolic adaptation that makes future weight loss harder.

How long does the first dose stay in my system? Tirzepatide has a half-life of about five days. After one dose, it takes roughly 25 days (five half-lives) to fully clear your system. However, blood levels drop to about 60% of peak by day seven, which is why weekly dosing is needed.

What should I do if I vomit after my first injection? If vomiting occurs more than two hours after injection, the medication has already been absorbed and you don't need to re-dose. If you vomit within 30 minutes of injection (rare), contact your provider to discuss whether a partial re-dose is appropriate. Persistent vomiting (more than two episodes in 24 hours) requires medical evaluation.

Can I drink alcohol after my first tirzepatide dose? Alcohol is not contraindicated, but tirzepatide slows gastric emptying, which can increase alcohol absorption and intensify its effects. Many patients report feeling intoxicated faster or experiencing worse hangovers. Limit alcohol intake, especially in the first week.

Will I feel hungry at all after the first dose? Yes. Tirzepatide reduces appetite, it doesn't eliminate it. You should still feel appropriate hunger signals before meals. If you have zero appetite for more than 48 hours or can't eat anything without feeling uncomfortably full, contact your provider.

What if I accidentally inject too much on my first dose? If you realize the error before injecting, push the excess back into the vial. If you've already injected, monitor for increased nausea, vomiting, or abdominal discomfort. Most small over-doses (e.g., 30 units instead of 25) cause no serious issues, but contact your provider if symptoms are severe or last longer than 72 hours.

Should I weigh myself daily after starting tirzepatide? Daily weighing can be helpful for tracking trends, but expect significant day-to-day fluctuations (2 to 4 pounds) from water retention, bowel content, and hormonal cycles. Weekly weigh-ins at the same time of day (e.g., Friday morning before eating) give a clearer signal.

Can I exercise normally after my first injection? Yes. Tirzepatide doesn't impair exercise capacity. Some patients report fatigue in the first few days, which may reduce workout intensity temporarily. Listen to your body and adjust as needed.

What if my injection site bleeds after the first dose? A small amount of bleeding (a drop or two) is normal and harmless. Apply gentle pressure with a clean tissue. If bleeding is persistent or you develop a large bruise, you may have hit a small blood vessel. It will resolve on its own but rotate to a different site for your next injection.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2023.
3. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2021.
4. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
5. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Investigation. 2008.
6. Chen W et al. Titration speed and treatment persistence in GLP-1 receptor agonist therapy: a retrospective cohort analysis. Obesity. 2024.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021.
11. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
13. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
14. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.